News | 08 June 2022
Merck and Ridgeback announce new data for investigational molnupiravir
Based on a post hoc analysis, fewer required respiratory interventions
Based on a post hoc analysis, fewer required respiratory interventions
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
The company has posted net profit of Rs.165.66 crores for the Financial Year ended March 31, 2022
Co-marketing agreement between Thermo Fisher Scientific and TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues
The company has launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The dashboard will serve as a single source of truth for public and PM-JAY stakeholders providing comprehensive view of scheme’s progress
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
The company has posted net loss of Rs. 67.65 crores for the Financial Year ended March 31, 2022
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
New Regional Processing Lab will serve Ahmedabad and the state of Gujarat
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
Subscribe To Our Newsletter & Stay Updated
